{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:16:15Z","timestamp":1684469775098},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T00:00:00Z","timestamp":1174348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncpneuro0471","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T15:10:26Z","timestamp":1174403426000},"page":"250-251","source":"Crossref","is-referenced-by-count":1,"title":["Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia"],"prefix":"10.1038","volume":"3","author":[{"given":"Caroline H","family":"Williams-Gray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,20]]},"reference":[{"key":"BFncpneuro0471_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D  et al. (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387\u2013392","journal-title":"Arch Neurol"},{"key":"BFncpneuro0471_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G  et al. (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123: 733\u2013745","journal-title":"Brain"},{"key":"BFncpneuro0471_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","volume":"20","author":"CH Williams-Gray","year":"2006","unstructured":"Williams-Gray CH  et al. (2006) Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20: 477\u2013505","journal-title":"CNS Drugs"},{"key":"BFncpneuro0471_CR4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M  et al. (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509\u20132518","journal-title":"N Engl J Med"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0471","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:29:17Z","timestamp":1684441757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,20]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncpneuro0471"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0471","relation":{},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,20]]}}}